Roche says Gazyva does not meet primary endpoint in phase III testing

July 18, 2016 5:30 AM

14 0

Roche says Gazyva does not meet primary endpoint in phase III testing

ZURICH Roche's Gazyva did not significantly reduce the risk of disease worsening or death compared to an alternative treatment for people with previously untreated diffuse large B-cell lymphoma in a phase III GOYA test, the company said on Monday.

"Two previous studies showed Gazyva/Gazyvaro helped people with previously untreated follicular lymphoma or chronic lymphocytic leukemia live longer without their disease worsening compared to MabThera/Rituxan, when each was combined with chemotherapy," Roche's Chief Medical Officer Sandra Horning s...

Also read: Oakland Warehouse Manager Tells 'Today' Show: 'I Am Incredibly Sorry'

Read more

To category page

Loading...